Table 1.

Adolescent acute lymphoblastic leukemia (ALL) outcome according to treatment protocol.2

SiteAge Range, yrNumber5-year EFSRef.
*7-year EFS 
Abbreviations: CCG, Children’s Cancer Group; CALGB, Cancer and Leukemia Group B; FRALLE, French Acute Lymphoblastic Leukemia Pediatric group; LALA, Leucémie Aiguë Lymphoblastique de l’Adulte; DCOG, Dutch Childhood Oncology Group; HOVON, Dutch-Belgian Hemato-Oncology Cooperative Group; UKALLXII-United Kingdom Acute Lymphoblastic Leukemia; NOPHO 92, Nordic Society of Pediatric Haematology and Oncology 
USA    34  
    CCG 16–21 197 63*  
    CALGB 16–21 124 34*  
France    35  
    FRALLE 93 15–20 77 67  
    LALA 94 15–20 100 41  
The Netherlands    36  
    DCOG 15–18 47 69  
    HOVON 15–18 44 34  
United Kingdom    37  
    MRC ALL 15–17 61 65  
    UKALLXII 15–17 67 49  
Sweden    38  
    NOPHO 92 15–18 36 74  
    Adult 15–20 21 39  
SiteAge Range, yrNumber5-year EFSRef.
*7-year EFS 
Abbreviations: CCG, Children’s Cancer Group; CALGB, Cancer and Leukemia Group B; FRALLE, French Acute Lymphoblastic Leukemia Pediatric group; LALA, Leucémie Aiguë Lymphoblastique de l’Adulte; DCOG, Dutch Childhood Oncology Group; HOVON, Dutch-Belgian Hemato-Oncology Cooperative Group; UKALLXII-United Kingdom Acute Lymphoblastic Leukemia; NOPHO 92, Nordic Society of Pediatric Haematology and Oncology 
USA    34  
    CCG 16–21 197 63*  
    CALGB 16–21 124 34*  
France    35  
    FRALLE 93 15–20 77 67  
    LALA 94 15–20 100 41  
The Netherlands    36  
    DCOG 15–18 47 69  
    HOVON 15–18 44 34  
United Kingdom    37  
    MRC ALL 15–17 61 65  
    UKALLXII 15–17 67 49  
Sweden    38  
    NOPHO 92 15–18 36 74  
    Adult 15–20 21 39  
Close Modal

or Create an Account

Close Modal
Close Modal